Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868471 | 0.86 | USP7 (1.00) | USP7USP19 | |
| SCHEMBL17868520 | 0.84 | USP7 (1.00) | USP7USP19 | |
| SCHEMBL17868484 | 0.82 | USP7 (1.00) | USP7USP19 | |
| SCHEMBL26036532 | 0.79 | USP7 (0.82) | USP7USP19 | |
| SCHEMBL26036538 | 0.79 | USP7 (0.82) | USP7USP19 | |
| SCHEMBL14735440 | 0.77 | USP7 (1.00) | USP7USP19 | |
| SCHEMBL17868481 | 0.76 | USP7 (1.00) | USP7USP19 | |
| SCHEMBL17868528 | 0.75 | USP7 (1.00) | USP7USP19 | |
| SCHEMBL24812665 | 0.75 | USP7 (0.80) | USP7USP19 | |
| SCHEMBL14744229 | 0.75 | USP7 (0.80) | USP7USP19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000495-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | claimed |
| EP-3240790-A1 | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER | Forma Therapeutics, Inc. (US) | 2017-11-08 | — | — | EP | claimed |
| WO-2016109480-A1 | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | claimed |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-06-30 | — | — | US | claimed |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220125760-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) | 2022-04-28 | — | — | US | disclosed |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2022-02-03 | — | — | US | disclosed |
| EP-3923987-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2021-12-22 | — | — | EP | disclosed |
| US-10981915-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| WO-2020165315-A1 | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-08-20 | — | — | WO | disclosed |
| US-20190308980-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10351571-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180339991-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-11-29 | — | — | US | disclosed |
| US-10000495-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| EP-3240790-A1 | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER | Forma Therapeutics, Inc. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109480-A1 | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Valo Health, LLC | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185786-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | USP7 1/4885USP19 25/4885 |
| US-10981915-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | USP7 1/4885USP19 25/4885 |
| US-20190308980-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | USP7 1/4885USP19 25/4885 |
| US-20220033403-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | USP7 1/4885USP19 25/4885 |
| US-20180339991-A1 | PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, PSMB7 | USP7 1/4885USP19 25/4885 |
| US-11795171-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | USP7 1/4885USP19 25/4885 |
| US-10351571-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | USP7 1/4885USP19 25/4885 |
| US-10000495-B2 | Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, PSMB7 | USP7 1/4885USP19 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.